Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting

BACKGROUND: Aflibercept (ziv-aflibercept) is an anti-angiogenic agent recently approved in combination with FOLFIRI for the treatment of metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin. Despite heterogeneity in response to aflibercept, no biomarkers for efficacy or a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambrechts, Diether, Thienpont, Bernard, Thuillier, Vincent, Sagaert, Xavier, Moisse, Matthieu, Peuteman, Gilian, Pericay, Carles, Folprecht, Gunnar, Zalcberg, John, Zilocchi, Chiara, Margherini, Emmanuelle, Chiron, Marielle, Van Cutsem, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651136/
https://www.ncbi.nlm.nih.gov/pubmed/26355232
http://dx.doi.org/10.1038/bjc.2015.329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651136/
https://www.ncbi.nlm.nih.gov/pubmed/26355232
http://dx.doi.org/10.1038/bjc.2015.329

Ejemplares similares